Edison Investment Research - Actinogen (ACW) Actinogen Medical - XanaCIDD study in MDD now underway

Report

Edison Investment Research

Sean Conroy

Actinogen Medical - XanaCIDD study in MDD now underway

Actinogen announced that the first patient was randomised and treated in its XanaCIDD Phase II study in major depressive disorder (MDD) assessing the effects of lead candidate Xanamem on cognitive performance and depression. The study aims to enrol about 160 patients who have persistent depressive symptoms and cognitive impairment (CI) despite taking standard-of-care (SoC) anti-depression therapy. Having demonstrated the ability to improve cognition in two trials (XanaHES and the Phase Ib portion of XanaMIA) in healthy adults, Actinogen is confident that Xanamem can exert similar cognitive improvement effects in MDD patients; this study will also explore whether the drug can have effects on depression as well. Results are expected in late 2023 or early 2024.

09/12/2022 1 EN

Underlying

Actinogen

Actinogen Medical is engaged in the undertaking of research of biological material obtained from field work and samples obtained from external sources for commercial applications. Co. operates predominantly in Australia.

See profile

AU000000ACW3 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

Actinogen Medical - A$11.1m capital raise completed

Actinogen Medical announced the successful completion of its A$3.0m share purchase plan (SPP), which closed 1.3x oversubscribed. With its previously disclosed A$8.1m share placement, total funds from the combined capital raising reached the targeted A$11.1m in gross proceeds. The company expects that the total proceeds will enable its operating runway to reach the release of top-line results for its XanaMIA Phase IIb/III trial in patients with mild-to-moderate Alzheimer’s disease (AD), expected in mid-CY26. The next major catalyst for Actinogen is the interim results on the first c 100 patient...

October 15, 2024 October 15, 2024 1 EN

Edison Investment Research

Actinogen Medical - Funding in place to complete XanaMIA Phase IIb

Actinogen Medical announced a capital increase of up to A$11.1m on 18 September, consisting of the successful completion of an A$8.1m (gross) share placement to existing shareholders and new institutional investors, along with a A$3.0m shareholder purchase plan (SPP) offer to existing shareholders at the same financial terms as the placement. The company expects that the proceeds (assuming full exercise of the SPP) will extend its operating runway to the completion of top-line results for its XanaMIA Phase IIb/III trial in patients with mild-to-moderate Alzheimer’s disease (AD), expected in mi...

October 7, 2024 October 7, 2024 1 EN

Edison Investment Research

Actinogen Medical - Further positive XanaCIDD results on depression

New data were revealed from Actinogen Medical’s ongoing analysis of the now-completed XanaCIDD study that support the view that the company’s lead drug candidate, Xanamem, may provide consistent and durable benefits in treating depression symptoms compared to placebo. The XanaCIDD study was designed to assess a 10mg daily dose of Xanamem versus placebo in patients with major depressive disorder (MDD) over a six-week treatment period. In line with the top-line results reported on 12 August, the new data confirm that maximal treatment effects on depression on all endpoints occurred at week 10, o...

August 27, 2024 August 27, 2024 1 EN

Nabaltec - Resilience and margin expansion

Nabaltec recorded revenue growth across the group of 1.5% y-o-y to €158.2m at 9M24, with sales volumes increasing 7.9% y-o-y despite selling prices falling. Functional Fillers revenue grew by 3.8% y-o-y to €114.1m due to strong demand for its viscosity optimised and fine precipitated aluminium hydroxides. Speciality Alumina revenue, however, decreased 4.1% y-o-y, partially offsetting group revenue growth due to a lack of impetus for reactive alumina in the wider market. Group EBIT grew 28.2% y-o-y to €16.8m (10.3% margin), due to higher capacity utilisation and lower costs of materials, energy...

11h / 3m 11h / 3m 1 EN

Kate Heseltine

Kate Heseltine

The Platform Group - Significant acceleration in growth in Q324

The Platform Group (TPG) reported a strong acceleration in revenue growth and profitability in Q324 as its growing industry presence and subsequent underlying growth provided an increase in most KPIs during the period. Its valuation continues to look attractive versus its online peers if management delivers on its expected growth rates.

13h / 19m 13h / 19m 1 EN

Toby Thorrington

Toby Thorrington

Theon International - Clear vision for growth

Theon International commands a unique position in military night vision systems as a market-leading business focused on man-portable systems (goggles). It has a market-leading position in Europe, an expanding presence globally and is developing adjacent product portfolios, most notably platforms like military vehicle vision systems. Its potential is supported by an addressable market of more than €3bn forecast to grow at double-digit rates. Combining this with a low capital-intensity business model should drive positive financials and strong cash generation.

15h / 3m 15h / 3m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Actinogen Medical - XanaCIDD study in MDD now underway

Actinogen Medical - A$11.1m capital raise completed

Actinogen Medical - Funding in place to complete XanaMIA Phase IIb

Actinogen Medical - Further positive XanaCIDD results on depression

Nabaltec - Resilience and margin expansion

The Platform Group - Significant acceleration in growth in Q324

Theon International - Clear vision for growth

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe